BIO vs GMED
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 27, 2026
BIO
GMED
Investment Advisor Scores
GMED
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIO | GMED | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 34.6021 | 16.6389 | GMED |
| PEG Ratio | 1.1905 | 1.7253 | BIO |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 1.1% | 27.0% | GMED |
| Earnings Growth | -83.0% | 66.7% | GMED |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 60.0/100 | 44.7/100 | BIO |
| Profit Margin | 6.5% | 18.9% | GMED |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | BUY | HOLD | BIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIO
MarkupPrice above SMA50, rising 50-day trend (5.7% over 20 days), RSI 67
GMED
DistributionPrice near a flattening SMA50 (slope -3.6%) with fading momentum, RSI 50
Fundamentals Snapshot
| Metric | BIO | GMED |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 33.5 | 15.3 |
| Trailing P/E | 54.4 | 19.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.3% |
| Gross Margin | 0.5% | 0.7% |
| Operating Margin | 0.1% | 0.2% |
| EPS | 6.01 | 4.22 |
| Dividend Yield | — | — |